Table 1.
Baseline characteristics, thromboembolic events, treatment overview, and outcome
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
|---|---|---|---|---|---|
| Age (y), sex | 63, female | 67, female | 41, female | 61, female | 61, female |
| Day of vaccination | 25 Feb 2021 | 15 Mar 2021 | 18 Mar 2021 | 15 Mar 2021 | 26 Mar 2021 |
| Hospital admission (day after vaccination) | 8 Mar 2021 (11) |
23 Mar 2021 (8) |
23 Mar 2021 (5) |
24 Mar 2021 (9) |
4 Apr 2021 (9) |
| Thromboembolic events (day of hospital stay) | CVST, TMA (1) |
Arterial cerebral embolism (1) |
TIA (1) |
SVT (6) |
Arterial cerebral thrombosis (1) Popliteal artery thrombosis (8) |
| Symptoms on admission | Headache, somnolence, dysphasia, right-sided hemiparesis, and arterial hypertension | Headache | Headache, diplopia | Fatigue | Headache, dysarthria, left-sided hemiplegia, conjugated gaze palsy |
| Imaging results | Left transverse and sigmoid sinus thrombosis Left temporal bleeding |
Cortical infarctions and aortic arch thrombi | No pathology | No pathology on admission. SVT day 6 after admission |
Right internal carotid and middle cerebral artery (M1) thrombosis. Right MCA territory infarction with hemorrhagic transformation |
| Platelet count on admission (/nL) | 27 | 40 | 105 | 12 | 62 |
| D-dimer on admission (mg/L) | >35.2 | >35.2 | 22.4 | >35.2 | >35.2 |
| Treatment | Heparin and eculizumab | Argatroban and IVIG | Argatroban | Argatroban, IVIG, alteplase (day 6), an eculizumab (day 7) | Argatroban and IVIG |
| Outcome | Recovering | Recovered | Recovered | Recovering | Recovering |
Patient 4 was first admitted to a remote hospital and transferred to Hannover Medical School on day 7 after admission. Please refer to supplemental Table 1 for additional laboratory parameters on admission and during follow-up.
TIA, transitory ischemic attack.